Abstract
This single-arm pilot study (NCT03329937) evaluated neoadjuvant niraparib antitumor activity and safety in patients with localized HER2-negative, BRCA-mutated breast cancer. Twenty-one patients received niraparib 200 mg once daily in 28-day cycles. After 2 cycles, tumor response (≥30% reduction from baseline) by MRI was 90.5% and 40.0% (6 of 15) of patients who received only niraparib (2–6 cycles) had pathological complete response; no new safety signals were identified. High niraparib intratumoral concentration was observed.
Original language | English (US) |
---|---|
Pages (from-to) | 927-931 |
Number of pages | 5 |
Journal | Nature Cancer |
Volume | 3 |
Issue number | 8 |
DOIs | |
State | Published - Aug 2022 |
ASJC Scopus subject areas
- Oncology
- Cancer Research